ABSTRACT Anthocyanins (Anthos; flower and kyanos; blue) are natural coloring compounds from the flavonoids class that include cyanidin, peonidin, delphinidin, malvidin, pelargonidin, and petunidin. Recently, the role of anthocyanins in disease prevention, especially inflammation, diabetes, cancer, neuro‐disorders, hepato‐renal protective, and immuno‐modulation properties has been highlighted. The current review covered the literature on the pharmacokinetics and pharmacological effects of anthocyanins, especially absorption, distribution, metabolism, and excretion (ADME). The discussion on molecular mechanisms underlying their therapeutic effects is the limelight of the article. The GLUT1, GLUT3, SGLT1, SMCT1, and SMCT2 are the main carriers involved in the transportation of anthocyanins in the gastrointestinal tract. The anthocyanins exert their anticancer effects by reducing the expression of IL‐6, IL‐1β, TNF‐β, COX‐2, downregulation of NF‐kB, EZH2, MDR1, Akt , and modulation of P13K/AKT and AMPK/mTOR pathways. The reduction in α‐amylase and α‐glucosidase and improved FFAR1 activity results in antidiabetic effects. The regulation of PGC‐1α/NRF2/TFAM, p‐PI3K/Akt/GSK3β, and Nrf2/HO‐1 prevents neurodegeneration. The anthocyanins impose hepato‐renal protective effects via ameliorating NLRP3 inflammasome, inhibiting MDA, GSSG, iNOS, HO‐1, ICAM‐1, β2‐microglobulin, and MPO activity, and improved SOD, CAT, and GSH activity. Anthocyanins promote beneficial gut microbiota and enhance SCFA production, thus inhibiting pro‐inflammatory markers. The immuno‐modulatory impact of anthocyanins involves the reduction of CRP, P‐selectin, C1q, and C4. Anthocyanins reduce LDL, VLDL, TGs, and TC via improved GBA and upregulation of ATP6 V0C, ZO‐1, and ATG4D expression. The WHO/FAO suggested that 2.5 mg/kg/day of grape‐skin extracts of anthocyanins are safe, and China recommended that 50 mg/day of anthocyanins are safe for consumption. In a nutshell, the multifaceted health benefits of anthocyanins make them promising candidates for disease prevention and therapeutic interventions.
BACKGROUND: Vascular endothelial growth factor receptor-2 (VEGFR-2) is a validated target in cancer therapy. However, approved inhibitors like sorafenib are often limited by off-target toxicity and resistance. This study aimed to develop novel thiadiazole-based VEGFR-2 inhibitors with improved selectivity and safer profiles. METHODS: A series of 2,3-dihydro-1,3,4-thiadiazole derivatives was rationally designed, synthesized, and structurally characterized. In vitro cytotoxicity was assessed against MCF-7, HepG-2, HCT-116, and normal WI-38 cells. Mechanistic assays included flow cytometry for cell cycle and apoptosis, and ELISA for caspase-3, Bcl-2, and Bax expression. Molecular docking, 200-ns molecular dynamics (MD) simulations, density functional theory (DFT) calculations, and in silico toxicity profiling supported experimental findings. RESULTS: Compound 11a exhibited the most potent and selective activity (IC₅₀: 9.49 µM for MCF-7, 12.89 µM for HepG-2; SI > 3). It induced >70% apoptosis and dual-phase (S and G2/M) cell cycle arrest. VEGFR-2 inhibition (IC₅₀ = 0.055 µM) was comparable to sorafenib. Computational studies confirmed stable binding at VEGFR-2 active sites. CONCLUSION: Compound 11a is a promising thiadiazole-based candidate with notable in vitro potency, selectivity, and mechanistic activity, supporting its potential for further pharmacokinetics/toxicity evaluation and structural refinement as a VEGFR-2-targeted agent.
VEGFR-2 inhibitorsthiadiazole derivativesanticancer drug discoveryapoptosis induction
Bioresources and Bioprocessing · مجلد 12 (1) · 21-21
Abstract Enzyme deployment is proliferating extensively in industries owing to their environmentally friendly and easily degradable attributes. This article undertakes an exhaustive examination of wild subtilisin enzyme, covering purification, biochemical delineation, analytical techniques, and practical implementations. The purification methodology involved partial refinement, anionic exchange, and gel filtration chromatography, culminating in a purification factor of 3.406, corroborated by SDS-PAGE showcasing a molecular weight of ~ 42 kDa. Biochemical scrutiny unveiled the enzyme's response, with an optimal pH at 9 and temperature peak at 60 ℃. Various surfactants, metal ions, organic solvents and inhibitors exhibited notable efficacy. Substrate specificity and kinetics showcased the utmost specificity with N-Suc-F-A-A-F- p NA, registering K m and V max values of 0.731 ± 0.5 mM and 0.87 ± 9 × 10 3 U/mg, respectively. Different bioanalytical techniquesproffered insights into structural and biophysical facets. Practical applications encompassed goat skin depilation, feather disintegration, blood clot dissolution, exemplifying the enzyme's multifaceted utility. To embark upon the elucidation of structure–function relationships, a three-dimensional model was devised through homology modelling, leveraging existing subtilisin structures (PDB: 3WHI). Molecular docking score of − 8.8 kcal/mol and dynamic simulations augmented the comprehension of molecular interactions with N-Suc-F-A-A-F- p NA. This research significantly contributes to unravelling the biochemical intricacies of wild subtilisin and underscores potential industrial and biomedical prowess. Subtilisin can be explored for its thrombolytic potential in several cardiovascular diseases. It may aid in the management of thrombosis by dissolving blood clots in conditions like deep pulmonary embolism, myocardial infarction, ischemic strokes, and in atherosclerosis by breaking down fibrin in arterial plaques, thus preventing heart attacks and strokes. Graphical Abstract
Comprehensive Reviews in Food Science and Food Safety · مجلد 24 (5) · e70276-e70276
ABSTRACT Fruits and vegetables, with high moisture levels of 85%–95% and 75%–96%, respectively, are susceptible to enzymatic activity and external factors, leading to rapid degradation through oxidative reactions, microbial proliferation, and respiration mechanisms such as ethylene emission. Drying, a critical preservation method, relies on heat and mass transfer driven by temperature and vapor pressure gradients. However, excessive thermal exposure and oxygen interaction often deteriorate bioactive compounds. Removing oxygen during drying offers a promising strategy to mitigate degradation and enhance product stability. Modified atmospheric drying (MAD) is an advanced technique that replaces atmospheric oxygen with alternative gases such as CO 2 , N 2 , or H 2 to improve drying efficiency and product quality. This review represents the first comprehensive effort to systematically consolidate recent developments in MAD, providing insights into operational mechanisms, equipment design, drying kinetics, quality preservation, and industrial feasibility, with emphasis on potential to reduce oxidation, retain nutrients, and preserve structural integrity. Compared to traditional drying, MAD achieves up to 18% improvement in effective moisture diffusivity, a 17%–29% reduction in drying time, and up to 6% increase in rehydration potential. It also enhances retention of nutritional and bioactive compounds, with total phenolic content maintained at 15%–25% higher levels, ascorbic acid degradation reduced by up to 15%, and improved color stability reflected in a decrease in total color difference (Δ E ) of up to 11%. CO 2 inhibits enzymes in aqueous and fatty matrices, whereas N 2 reduces oxidative and microbial deterioration. Overall, MAD improves product quality, shelf life, and energy efficiency, lowering production costs.
fruit dryingvegetable dryingdrying kineticsoxygen removal
mechanistic studies further confirmed the activation of the intrinsic apoptotic pathway, as evidenced by caspase-3 activation (8.2-fold), Bax upregulation (6.9-fold), and Bcl-2 downregulation (3.68-fold). Computational studies, including molecular docking and 200 ns molecular dynamics (MD) simulations, confirmed the stable interaction of 7a with VEGFR-2, showing binding affinities comparable to sorafenib. Further validation through MM-GBSA, ProLIF, PCAT, and FEL analyses reinforced its strong binding capability. Additionally, ADMET predictions suggested favorable pharmacokinetic properties, including good absorption, high plasma protein binding, and non-CYP2D6 inhibition. Moreover, toxicity analysis classified 7a as non-mutagenic and non-carcinogenic, with a lower predicted toxicity than sorafenib. Finally, density functional theory (DFT) calculations highlighted the structural stability and reactivity of 7a, further supporting its potential as a VEGFR-2 inhibitor. These findings suggest that 7a is a promising VEGFR-2 inhibitor with significant anticancer potential, favorable pharmacokinetics, and an improved safety profile. Further preclinical studies and structural modifications are warranted to optimize its therapeutic potential.
Cancer is a leading global cause of death, with complex pathogenesis and treatment challenges like poor selectivity, toxicity, and drug resistance. Nanotechnology offers transformative solutions, with plant-derived exosomes (EXOs) emerging as promising green nanomaterials for personalized cancer therapy because of their biocompatibility and minimal antigenicity, and eco-friendly production. This review discusses the potential of plant EXOs in cancer treatment, covering isolation methods, advantages over mammalian EXOs (e.g., stability, cost-effectiveness, and evasion of drug resistance mechanisms), and preclinical applications. For instance, ginger EXOs suppress colorectal cancer via cytokine modulation, grapefruit EXOs target brain tumors, and lemon EXOs induce apoptosis in triple-negative breast cancer. Plant EXOs also enhance drug delivery when loaded with chemotherapeutics, nucleic acids, or immunomodulators, improving precision and reducing off-target effects. Despite their promise, challenges remain in scalability, purity, long-term safety for non-oral routes, and clinical translation. Future research must optimize isolation techniques, clarify molecular mechanisms, and validate pharmacokinetics to advance clinical adoption. This review offers a complete examination of plant EXOs, including biogenesis, characterization, engineering strategies, anti-cancer mechanisms (e.g., apoptosis induction, immune modulation), and therapeutic applications. It also addresses hurdles like standardization and regulatory gaps while advocating interdisciplinary collaboration to bridge lab-to-clinic gaps. By harnessing plant EXOs' potential, this work highlights a path toward sustainable, targeted cancer therapies, urging further innovation to overcome existing barriers and realize their full clinical impact.
Drug Development and Industrial Pharmacy · مجلد 51 (8) · 930-942
PURPOSE: To address the challenges of frequent glipizide dosing, including its variable bioa-vailability and gastrointestinal side effects, this study developed and evaluated mucoadhesive buccal films using natural proteins (albumin, gelatin, casein) combined with HPMC E15 to achieve sustained drug delivery. METHODS: Nine formulations (F1-F9) were prepared using solvent casting technique and sys-tematically characterized. Comprehensive evaluations included: (1) drug-polymer compatibil-ity studies (FT-IR, DSC), (2) physicochemical characterization (thickness, weight uniformity, swelling index, moisture content, folding endurance, surface pH), (3) ex-vivo permeation studies through sheep buccal mucosa, and (4) stability assessments to determine film longevi-ty. RESULTS: Compatibility studies utilizing FT-IR and DSC confirmed no significant incompati-bility between glipizide and the excipients. Some of the important physicochemical character-istics recorded for different formulations were surface pH (6.6 - 6.8), folding endurance (72 - 184), moisture content (5.66 - 12.54%), thickness (0.171 - 0.236 mm), weight (0.150 - 0.238 mg), and swelling index (15.8% after 1 hour to 86.6% after 5 hours). Furthermore, neg-ligible variation was observed in these characteristics when stability studies were conducted after 3 months. The ex-vivo permeation studies demonstrated a sustained release of glipizide over 8 hours, with release percentages ranging from 80.94% to 90%. Formulation F6, which achieved an 8-hour release of 89.29%, was identified as optimal. Kinetic analysis revealed zero-order release kinetics for all formulations. CONCLUSION: The developed mucoadhesive buccal films exhibited excellent sustained-release properties, representing a significant improvement over conventional dosage forms. This in-novative delivery system shows strong potential for enhancing diabetes management through improved bioavailability and patient compliance, while minimizing gastrointestinal side effects.
mucoadhesive buccal filmsglipizidesustained drug releasenatural proteins
Background Thieno-pyrimidine derivatives have emerged as promising candidates for VEGFR-2 inhibition. This study aimed to design, synthesize, and evaluate novel thieno-pyrimidine derivatives for their anti-cancer potential.Methods A series of thieno-pyrimidine compounds were synthesized and screened for in vitro cytotoxicity against MDA-231 and MCF-7 cell lines. The most active compound, 6b, was further analyzed for VEGFR-2 kinase inhibition, wound healing, apoptosis induction, and cell cycle arrest. Molecular docking, 200 ns molecular dynamics simulations, MM-GBSA, ProLIF PCAT, and FEL analyses were conducted to assess binding stability. DFT calculations evaluated electronic properties, while in silico ADMET profiling predicted pharmacokinetics and toxicity.Results Compound 6b exhibited potent cytotoxicity with IC50 values of 5.91 µM (MDA-231) and 7.16 µM (MCF-7). It demonstrated VEGFR-2 inhibition is comparable to sorafenib (IC50: 53.63 ± 3.14 nM). Wound healing assays showed significant inhibition of MDA-231 migration. Flow cytometry confirmed apoptosis induction (57.20% early apoptosis) and G1 phase arrest. Gene expression analysis revealed upregulation of pro-apoptotic markers and downregulation of Bcl-2. Computational studies confirmed stable VEGFR-2 binding, and ADMET predictions indicated a favorable safety profile.Conclusion Compound 6b exhibits strong VEGFR-2 inhibition, potent anti-cancer effects, and a favorable toxicity profile, highlighting its potential for further therapeutic development.